Fig 1.
Flow chart showing management and pregnancy outcome of 67 fetuses with prenatally diagnosed CPAM.
Fig 2.
Transverse section of the fetal thorax at 25 weeks of gestation demonstrating a macrocystic congenital pulmonary airway malformation (CPAM) drained by an inserted double pigtail catheter (Harrison Fetal Bladder Stent Set).
Table 1.
Outcome of fetuses with intrauterine treatment of congenital pulmonary airway malformation.
Fig 3.
Transverse and longitudinal section of the fetal thorax demonstrating a large microcystic congenital pulmonary airway malformation (CPAM) with mediastinal shift at 19 weeks of gestation.
CVR (CPAM volume ratio): 2.88 x 1.77 x 2.31 x 0.52/16.1 (head circumference) = 0.38.
Fig 4.
Receiver operator characteristics curve for the congenital pulmonary airway malformation-volume ratio (CVR) and composite adverse outcome or need for intervention.
Fig 5.
Transverse section of the fetal thorax at 19 weeks of gestation demonstrating a large macrozystic congenital pulmonary airway malformation (CPAM) with severe mediastinal shift.
MTR (Mass-to-thorax ratio): 26.9 / 42.3 = 0.63.
Fig 6.
Receiver operator characteristics curve for Mass-to-thorax ratio (MTR) and composite adverse outcome or need for intervention.
Fig 7.
Receiver operator characteristics curve for observed to expected lung-to-head ratio (o/e LHR) and composite adverse outcome or need for intervention.
Fig 8.
Detectionrate in % of adverse events (perinatal death, hydrops, prenatal intervention or need for respiratory assistance) at a cutoff of 0.51 mass-to-thorax rate (MTR) in comparison to fetuses without adverse events.
Fig 9.
Detectionrate in % of adverse events (perinatal death, hydrops, prenatal intervention or need for respiratory assistance) at a cutoff of 0.91 CPAM volume ratio (CVR) in comparison to fetuses without adverse events.
Fig 10.
Detectionrate in % of adverse events (perinatal death, hydrops, prenatal intervention or need for respiratory assistance) at a cutoff of 45% observed to expected Lung to head ratio (LHR) in comparison to fetuses without adverse events.